Todas as matérias desta seção, das mais recentes às mais antigas — página 241 de 371.
Innate Pharma (NASDAQ:IPHA), a clinical-stage biotechnology company developing next-generation immunotherapies for cancer, today reported its consolidated financial results for the full year ended December 31, 2025.
Meta Platforms (NASDAQ:META) is executing a strategic reorganization of its nearly 79,000-person workforce, laying off 700 employees across Reality Labs, social media, sales, and talent acquisition.
Hyperion DeFi (NASDAQ:HYPD), the inaugural U.S. publicly traded entity dedicated to the Hyperliquid ecosystem, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Novocure (NASDAQ:NVCR), a global oncology company at the forefront of cancer treatment innovation, today announced positive topline results from its Phase 2 PANOVA-4 clinical trial.
BioLineRx (NASDAQ:BLRX), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the initiation of a first-in-human Phase 1/2a clinical trial evaluating GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.
MeiraGTx Holdings (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive update on its late-stage clinical pipeline.
Foresight Autonomous Holdings (NASDAQ:FRSX), an innovator in automotive vision systems, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Interlink Electronics (NASDAQ:LINK), a global leader in human-machine interface and sensor technologies, today reported financial results for the fourth quarter ended December 31, 2025.
Formula Systems (NASDAQ:FORTY), a global information technology holding company, today reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.
CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies based on its proprietary plant-derived recombinant human collagen (rhCollagen), today reported financial results for the full year ended December 31, 2025.
MetaVia (NASDAQ:MTVA), a clinical-stage biopharmaceutical company developing novel therapies for obesity and metabolic-associated steatohepatitis (MASH), today reported financial results for the full year ended December 31, 2025, and provided an update on its advancing clinical pipeline.
ParaZero Technologies (NASDAQ:PRZO), an aerospace company focused on drone safety systems for commercial and defense applications, today reported its financial results for the full year ended December 31, 2025.
OceanPal (NASDAQ:SVRN), a company historically focused on the dry bulk shipping sector, today reported its financial results for the full year ended December 31, 2025
The Dixie Group (NASDAQ:DXYN), a prominent developer and manufacturer of high-end floor covering products, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biopharmaceutical company focused on developing novel bispecific and multispecific immunotherapies for cancer, today reported financial results for the year ended December 31, 2025, and provided a strategic business update.
Cognition Therapeutics (NASDAQ:CGTX), a clinical-stage biopharmaceutical company developing next-generation therapies for neurodegenerative disorders, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive update on its lead candidate, zervimesine (CT1812).
REX American Resources (NYSE:REX), a player in the U.S. ethanol industry, today reported financial results for its fiscal fourth quarter and full year ended January 31, 2026.
MapLight Therapeutics (NASDAQ:MPLT), a biopharmaceutical company focused on circuit-specific therapies for central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Acumen Pharmaceuticals (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel targeted immunotherapy for Alzheimer’s disease, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive business update.
The Lovesac Company (NASDAQ:LOVE), the omni-channel home brand famous for its "Designed for Life" Sactionals, today announced financial results for the fourth quarter and full fiscal year ended February 1, 2026.
WhiteFiber (NASDAQ:WYFI), a vertically integrated provider of artificial intelligence (AI) infrastructure and high-performance computing (HPC) solutions, today reported its financial results for the fourth quarter and full year ended December 31, 2025.
Commercial Metals Company (NYSE:CMC), a global leader in innovative solutions for the built environment, today reported financial results for its fiscal second quarter ended February 28, 2026.
Designer Brands (NYSE:DBI), the parent company of DSW and a global leader in brand development and footwear retail, today reported its financial results for the fourth quarter and full fiscal year ended January 31, 2026.
Worthington Steel (NYSE:WS), a value-added metals processor, today reported financial results for its fiscal 2026 third quarter ended February 28, 2026.
